Levobens

Levodopa/Benserazide, the active ingredients in Levobens, are a dopamine precursor and a dopa decarboxylase inhibitor presented as a tablet for oral use. They are prescribed to improve motor function in patients with Parkinson's disease and related Parkinsonian syndromes.

GNH USA supplies Levobens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levobens is used within the dopaminergic pathway to manage Parkinsonian disorders.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: restores dopamine levels to alleviate movement impairments. - Motor fluctuations in Parkinson's disease: reduces OFF periods and enhances overall motor stability.

Levobens may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating sleep. - Dyskinesia: involuntary movements at higher doses. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Severe hypotension: marked blood pressure drop requiring medical attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms. - Severe dyskinesia: disabling involuntary movements. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Levobens, clinicians should consider several safety measures.

- Monitor blood pressure: check for orthostatic changes, especially at treatment initiation. - Assess psychiatric status: watch for hallucinations or confusion. - Adjust dose in renal impairment: consider reduced dosing or increased monitoring. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Store at below 25°C: keep in the original pack, protect from moisture.

Levobens can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk hypertensive crisis. - Anticholinergics: may mask motor symptom improvement. - Iron or calcium supplements: reduce levodopa absorption.

Moderate Interactions (Monitor Closely): - High‑protein meals: may decrease levodopa bioavailability. - Other dopamine agonists: additive effect on dyskinesia. - SSRIs or SNRIs: potential for serotonin syndrome in rare cases.